Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Obese Children

被引:20
|
作者
Hecht, Lior [1 ,2 ]
Weiss, Ram [1 ,2 ,3 ]
机构
[1] Hadassah Hebrew Univ Sch Med, Dept Human Metab & Nutr, IL-91120 Jerusalem, Israel
[2] Hadassah Hebrew Univ Sch Med, Sect Pediat Endocrinol, IL-91120 Jerusalem, Israel
[3] Hadassah Hebrew Univ Sch Med, Dept Human Metab & Nutr, Braun Sch Publ Hlth, IL-91120 Jerusalem, Israel
关键词
Nonalcoholic fatty liver disease (NAFLD); Insulin resistance; Insulin clearance; Type; 2; diabetes; INSULIN-RESISTANCE; METABOLIC SYNDROME; GLUCOSE-TOLERANCE; HEPATIC STEATOSIS; SKELETAL-MUSCLE; GUT MICROBIOTA; ADOLESCENTS; PREVALENCE; ADIPONECTIN; ASSOCIATION;
D O I
10.1007/s11892-013-0448-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nonalcoholic fatty liver disease (NAFLD) is commonly found in adults and adolescents with type 2 diabetes (T2DM). The cause-effect relations of these 2 conditions are complex and it is difficult to decipher whether one drives the other or vice versa. Genetic predispositions, along with obesity, are probably shared culprits of both. NAFLD may precede the diagnosis of diabetes and play a critical role of driving its development by way of increasing hepatic and whole body insulin resistance. On the other hand, T2DM is associated with hyperinsulinemia, a resistance to some of the effects of gut derived peptides and increased systemic free fatty acids, that can all promote hepatic lipid deposition. Thus, each condition may promote the development of the other and their mutual presence creates a vicious cycle. Upon studying this complex interplay from another angle, reduction of liver fat significantly improves glucose metabolism in patients with T2DM highlighting the tight pathophysiological link between them.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Type 2 diabetes, congestive heart failure and nonalcoholic fatty liver disease
    Maechler, M.
    Vonbank, A.
    Larcher, B.
    Mader, A.
    Sprenger, L.
    Leiherer, A.
    Zanolin-Purin, D.
    Muendlein, A.
    Drexel, H.
    Saely, C. H.
    WIENER KLINISCHE WOCHENSCHRIFT, 2020, 132 : S214 - S214
  • [32] The effect of liraglutide on nonalcoholic fatty liver disease in type 2 diabetes mellitus
    Xueyang Zhang
    Ran Bai
    Yong Jia
    Junwei Zong
    Yongbo Wang
    Yanan Dong
    International Journal of Diabetes in Developing Countries, 2020, 40 : 491 - 499
  • [33] Nonalcoholic Fatty Liver Disease The New Complication of Type 2 Diabetes Mellitus
    Bril, Fernando
    Cusi, Kenneth
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2016, 45 (04) : 765 - +
  • [34] Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Common Pathophysiologic Mechanisms
    Saponaro, Chiara
    Gaggini, Melania
    Gastaldelli, Amalia
    CURRENT DIABETES REPORTS, 2015, 15 (06) : 1 - 13
  • [35] Type 2 Diabetes, Congestive Heart Failure, and Nonalcoholic Fatty Liver Disease
    Maechler, Maximilian
    Vonbank, Alexander
    Larcher, Barbara
    Mader, Arthur
    Sprenger, Lukas
    Leiherer, Andreas
    Purin, Daniela
    Muendlein, Axel
    Drexel, Heinz
    Saely, Christoph H.
    DIABETES, 2020, 69
  • [36] Nonalcoholic fatty liver disease and the risk of type 2 diabetes in the United States
    Clark, JM
    Diehl, AM
    Brancati, FL
    DIABETES, 2001, 50 : A38 - A39
  • [37] Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: The Hidden Epidemic
    Ismail, Mona H.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2011, 341 (06): : 485 - 492
  • [38] The effect of liraglutide on nonalcoholic fatty liver disease in type 2 diabetes mellitus
    Zhang, Xueyang
    Bai, Ran
    Jia, Yong
    Zong, Junwei
    Wang, Yongbo
    Dong, Yanan
    INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2020, 40 (04) : 491 - 499
  • [39] Increased Serum Pentraxin 3 Is Associated with Prediabetes and Type 2 Diabetes in Obese Patients with Nonalcoholic Fatty Liver Disease
    Karamfilova, Vera
    Assyov, Yavor
    Nedeva, Iveta
    Gateva, Antoaneta
    Ivanova, Irena
    Cherkezov, Nikolay
    Mateva, Ludmila
    Kamenov, Zdravko
    METABOLIC SYNDROME AND RELATED DISORDERS, 2022, 20 (02) : 132 - 136
  • [40] Combining metformin therapy with caloric restriction for the management of type 2 diabetes and nonalcoholic fatty liver disease in obese rats
    Linden, Melissa A.
    Lopez, Kristi T.
    Fletcher, Justin A.
    Morris, E. Matthew
    Meers, Grace M.
    Siddique, Sameer
    Laughlin, M. Harold
    Sowers, James R.
    Thyfault, John P.
    Ibdah, Jamal A.
    Rector, R. Scott
    APPLIED PHYSIOLOGY NUTRITION AND METABOLISM, 2015, 40 (10) : 1038 - 1047